FI935151A - Foerfaranden foer diastereoselektiv syntes av nukleosider - Google Patents

Foerfaranden foer diastereoselektiv syntes av nukleosider Download PDF

Info

Publication number
FI935151A
FI935151A FI935151A FI935151A FI935151A FI 935151 A FI935151 A FI 935151A FI 935151 A FI935151 A FI 935151A FI 935151 A FI935151 A FI 935151A FI 935151 A FI935151 A FI 935151A
Authority
FI
Finland
Prior art keywords
nucleosider
reference factor
diastereoselective synthesis
diastereoselective
synthesis
Prior art date
Application number
FI935151A
Other languages
English (en)
Other versions
FI106377B (fi
FI935151A0 (fi
Inventor
Tarek Mansour
Haolun Jin
Allan Tse
M Arshad Siddiqui
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24825144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI935151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of FI935151A publication Critical patent/FI935151A/fi
Publication of FI935151A0 publication Critical patent/FI935151A0/fi
Priority to FI960286A priority Critical patent/FI102279B/fi
Application granted granted Critical
Publication of FI106377B publication Critical patent/FI106377B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Vehicle Step Arrangements And Article Storage (AREA)
FI935151A 1991-05-21 1993-11-19 Menetelmiä nukleosidien diastereoselektiiviseen synteesiin FI106377B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI960286A FI102279B (fi) 1991-05-21 1996-01-19 Välituotteita nukleosidien diastereoselektiivisiin synteesimenetelmiin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70337991A 1991-05-21 1991-05-21
US70337991 1991-05-21
PCT/CA1992/000211 WO1992020669A1 (en) 1991-05-21 1992-05-20 Processes for the diastereoselective synthesis of nucleosides
CA9200211 1992-05-20

Publications (3)

Publication Number Publication Date
FI935151A true FI935151A (fi) 1993-11-19
FI935151A0 FI935151A0 (fi) 1993-11-19
FI106377B FI106377B (fi) 2001-01-31

Family

ID=24825144

Family Applications (3)

Application Number Title Priority Date Filing Date
FI935151A FI106377B (fi) 1991-05-21 1993-11-19 Menetelmiä nukleosidien diastereoselektiiviseen synteesiin
FI935150A FI109025B (fi) 1991-05-21 1993-11-19 Diastereoselektiivinen menetelmä optisesti aktiivisten cis-nukleosidien valmistamiseksi
FI20001900A FI20001900A (fi) 1991-05-21 2000-08-29 Välituotteet

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI935150A FI109025B (fi) 1991-05-21 1993-11-19 Diastereoselektiivinen menetelmä optisesti aktiivisten cis-nukleosidien valmistamiseksi
FI20001900A FI20001900A (fi) 1991-05-21 2000-08-29 Välituotteet

Country Status (34)

Country Link
US (5) US5756706A (fi)
EP (2) EP0515157B1 (fi)
JP (3) JP3229013B2 (fi)
KR (3) KR0160144B1 (fi)
CN (6) CN1035555C (fi)
AT (2) ATE157662T1 (fi)
AU (4) AU668086B2 (fi)
BG (2) BG61695B1 (fi)
CA (2) CA2069063C (fi)
CZ (3) CZ285220B6 (fi)
DE (2) DE69221936T2 (fi)
DK (2) DK0515157T3 (fi)
EE (1) EE03044B1 (fi)
ES (2) ES2084937T3 (fi)
FI (3) FI106377B (fi)
GR (2) GR3018941T3 (fi)
GT (1) GT199800047A (fi)
HK (2) HK132196A (fi)
HU (2) HU223838B1 (fi)
IE (2) IE921618A1 (fi)
IL (6) IL101931A (fi)
MD (1) MD1155C2 (fi)
MX (2) MX9202404A (fi)
NO (2) NO300593B1 (fi)
NZ (2) NZ242817A (fi)
OA (1) OA10212A (fi)
PL (3) PL176026B1 (fi)
RO (1) RO116812B1 (fi)
RU (4) RU2140925C1 (fi)
SG (1) SG43863A1 (fi)
SK (2) SK281954B6 (fi)
TW (4) TW366350B (fi)
WO (2) WO1992020669A1 (fi)
ZA (2) ZA923640B (fi)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684164A (en) 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
AU3154993A (en) * 1989-02-08 1994-07-19 Biochem Pharma Inc. Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
CA2171550C (en) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
ZA969220B (en) * 1995-11-02 1997-06-02 Chong Kun Dang Corp Nucleoside derivatives and process for preparing the same
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
EP0799834A1 (en) * 1996-04-04 1997-10-08 Novartis AG Modified nucleotides
US6005097A (en) * 1996-06-14 1999-12-21 Vion Pharmaceuticals, Inc. Processes for high-yield diastereoselective synthesis of dideoxynucleosides
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6022876A (en) 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
WO1998035977A1 (en) 1997-02-13 1998-08-20 Glaxo Group Limited Benzimidazole derivatives
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
CA2293470C (en) 1997-06-10 2008-05-13 Glaxo Group Limited Benzimidazole derivatives
US6455506B1 (en) 1997-07-30 2002-09-24 Smithkline Beecham Corporation Lyxofuranosyl benzimidazoles as antiviral agents
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
KR100856416B1 (ko) 1998-08-12 2008-09-04 길리애드 사이언시즈, 인코포레이티드 1,3-옥사티올란 뉴클레오시드의 제조 방법
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
OA11741A (en) 1998-12-23 2005-05-13 Iaf Biochem Int Antiviral nucleoside analogues.
US7115584B2 (en) 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
CA2385349A1 (en) 1999-09-24 2001-04-05 Francis J. Giles Method for the treatment or prevention of viral infection using nucleoside analogues
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) * 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
KR101015510B1 (ko) * 2001-03-01 2011-02-16 길리애드 사이언시즈, 인코포레이티드 시스-ｆｔｃ의 다형 및 기타 결정형
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
WO2003033526A2 (en) * 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
ITMI20012317A1 (it) * 2001-11-06 2003-05-06 Recordati Ind Chimica E Farma Processo diastereoselettivo per la preparazione del'agente antivirale4-amino-1-(2r-idrossimetil-/1,3/ossatiolan-5s-i1)-1h-pirimidin-2-one
WO2003051298A2 (en) * 2001-12-14 2003-06-26 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
WO2003062229A1 (en) 2002-01-25 2003-07-31 Shire Biochem Inc. Process for producing dioxolane nucleoside analogues
US7365173B2 (en) * 2002-02-04 2008-04-29 American National Red Cross Method for the production of pure virally inactivated butyrylcholinesterase
ES2360096T3 (es) 2002-08-06 2011-05-31 Pharmasset, Inc. Procedimientos de preparación de nucleosidos de 1,3-dioxolano.
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
US7785839B2 (en) 2004-02-03 2010-08-31 Emory University Methods to manufacture 1,3-dioxolane nucleosides
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
NZ585697A (en) * 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US20060042638A1 (en) * 2004-08-31 2006-03-02 Niklewski Paul J Apparatus for delivering oxygen to a patient undergoing a medical procedure
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP2086955A2 (en) * 2006-10-30 2009-08-12 Lupin Ltd. An improved process for the manufacture of cis(-)-lamivudine
MX2010003261A (es) 2007-09-26 2010-08-18 Sinai School Medicine Analogos de azacitidina y usos de los mismos.
BRPI0820224A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
SI2225232T1 (sl) * 2007-11-29 2012-12-31 Ranbaxy Laboratories Limited Postopek za pripravo substituiranih 1,3-oksatiolanov
US8350030B2 (en) 2007-12-07 2013-01-08 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
US20110282046A1 (en) 2009-01-19 2011-11-17 Rama Shankar Process for preparation of cis-nucleoside derivative
KR101738325B1 (ko) 2009-02-06 2017-05-19 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
US20140046062A1 (en) * 2010-01-08 2014-02-13 Bandi Parthasaradhi Reddy Process for nucleosides
TR201807704T4 (tr) 2010-01-27 2018-06-21 Viiv Healthcare Co Anti-viral tedavi.
WO2011095987A1 (en) * 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
EP2542551B1 (en) 2010-03-04 2014-08-27 Ranbaxy Laboratories Limited A process for stereoselective synthesis of 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
WO2012062835A1 (en) 2010-11-12 2012-05-18 Glaxo Wellcome Manufacturing Pte Ltd Novel pharmaceutical compositions
WO2013021290A1 (en) 2011-08-05 2013-02-14 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
UA116528C2 (uk) 2011-08-30 2018-04-10 Астекс Фармасьютікалз, Інк. Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
CN103242243B (zh) * 2013-01-08 2015-08-19 北京大学 一种碱基乙酸甘油醚酯分子,其化学合成方法及其在基因治疗领域的应用
CN103288806A (zh) * 2013-07-02 2013-09-11 山东大学 一种曲沙他滨的合成方法
US10485764B2 (en) 2015-07-02 2019-11-26 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105037340B (zh) * 2015-07-14 2018-08-10 福建广生堂药业股份有限公司 一种拉米夫定关键中间体手性异构体杂质的制备方法
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1445013A (fr) * 1964-07-09 1966-07-08 Thomae Gmbh Dr K Procédé pour fabriquer des nouveaux acides dioxolano-2-carboxyliques
US4383114A (en) * 1977-02-09 1983-05-10 Regents Of The University Of Minnesota Adenosine deaminase resistant antiviral purine arabinonucleosides
US4231945A (en) * 1978-11-08 1980-11-04 Schering Corporation S-5-(Azidomethyl or aminomethyl)-2-lower-alkoxytetrahydrofurans
US4479942A (en) * 1981-08-10 1984-10-30 Fujisawa Pharmaceutical Co., Ltd. Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof
US4855304A (en) * 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
DK363987A (da) * 1986-08-08 1988-02-09 Hoffmann La Roche Pyrimidinderivater
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
US4997818A (en) * 1987-09-21 1991-03-05 The University Hospital Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
JPH022349A (ja) * 1988-02-17 1990-01-08 Takeda Chem Ind Ltd ピリミジンアナログ耐性化遺伝子ｄｎａおよびその用途
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE3823127A1 (de) * 1988-07-08 1990-01-11 Rheinische Braunkohlenw Ag Vorrichtung und verfahren zur reinigung von abwasser
US4987224A (en) * 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
DE3827134A1 (de) * 1988-08-10 1990-03-15 Bayer Ag Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung
US5075225A (en) * 1989-04-06 1991-12-24 The Texas A&M University System Process for the enzymatic synthesis of nucleosides
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9014090D0 (en) * 1990-06-25 1990-08-15 Zaadunie Bv Improvements in or relating to organic compounds
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides

Also Published As

Publication number Publication date
DK0515157T3 (da) 1997-09-29
SK129493A3 (en) 1994-11-09
DE69208144D1 (de) 1996-03-21
TW366349B (en) 1999-08-11
RU2163909C2 (ru) 2001-03-10
FI106377B (fi) 2001-01-31
CZ284975B6 (cs) 1999-04-14
DE69221936T2 (de) 1998-01-02
HU221850B1 (hu) 2003-02-28
OA10212A (en) 1997-10-07
EP0515156B1 (en) 1996-02-07
IL116109A0 (en) 1996-01-31
NO921989L (no) 1992-11-23
NZ242817A (en) 1995-03-28
MD1155B2 (en) 1999-02-28
ATE133958T1 (de) 1996-02-15
CZ222496A3 (cs) 1999-04-14
CA2069024A1 (en) 1992-11-22
ES2104832T3 (es) 1997-10-16
EP0515157A1 (en) 1992-11-25
WO1992020669A1 (en) 1992-11-26
KR920021576A (ko) 1992-12-18
ATE157662T1 (de) 1997-09-15
CA2069024C (en) 1997-09-23
EP0515157B1 (en) 1997-09-03
HK132196A (en) 1996-07-26
TW366350B (en) 1999-08-11
CN1109030C (zh) 2003-05-21
TWI245046B (en) 2005-12-11
JPH05186465A (ja) 1993-07-27
AU1639592A (en) 1992-11-26
AU668086B2 (en) 1996-04-26
EE03044B1 (et) 1997-10-15
HU9303297D0 (en) 1994-03-28
ES2084937T3 (es) 1996-05-16
CN1229080A (zh) 1999-09-22
DE69221936D1 (de) 1997-10-09
AU1690892A (en) 1992-12-30
DK0515156T3 (da) 1996-06-17
NO921988L (no) 1992-11-23
RO116812B1 (ro) 2001-06-29
FI935150A0 (fi) 1993-11-19
RU2140925C1 (ru) 1999-11-10
CZ280857B6 (cs) 1996-04-17
IL116176A (en) 1998-02-08
GR3018941T3 (en) 1996-05-31
SK279438B6 (sk) 1998-11-04
HU9303296D0 (en) 1994-03-28
EP0515156A1 (en) 1992-11-25
JP3330972B2 (ja) 2002-10-07
IE921619A1 (en) 1992-12-02
HUT67726A (en) 1995-04-28
HUT67471A (en) 1995-04-28
CZ285220B6 (cs) 1999-06-16
KR0160144B1 (ko) 1998-11-16
SK281954B6 (sk) 2001-09-11
CN1067245A (zh) 1992-12-23
AU1639492A (en) 1992-11-26
CA2069063C (en) 1997-07-15
IL101931A0 (en) 1992-12-30
US5756706A (en) 1998-05-26
KR100232012B1 (ko) 1999-12-01
CN1083450C (zh) 2002-04-24
SG43863A1 (en) 1997-11-14
WO1992020696A1 (en) 1992-11-26
CN1097049C (zh) 2002-12-25
PL176026B1 (pl) 1999-03-31
JP3704055B2 (ja) 2005-10-05
CZ249393A3 (en) 1994-04-13
CN1116204A (zh) 1996-02-07
CN1229079A (zh) 1999-09-22
RU2105009C1 (ru) 1998-02-20
ZA923641B (en) 1993-02-24
NO921988D0 (no) 1992-05-20
HK1002431A1 (en) 1998-08-21
MD1155C2 (ro) 1999-10-31
IL116176A0 (en) 1996-01-31
IL101932A0 (en) 1992-12-30
AU1691392A (en) 1992-12-30
AU655973B2 (en) 1995-01-19
JP2001354667A (ja) 2001-12-25
BG98311A (bg) 1994-08-30
CZ249293A3 (en) 1994-03-16
ZA923640B (en) 1993-02-24
CN1038591C (zh) 1998-06-03
MD950172A (en) 1996-08-30
BG61695B1 (bg) 1998-03-31
IL101931A (en) 1996-12-05
FI109025B (fi) 2002-05-15
BG61696B1 (bg) 1998-03-31
PL170869B1 (pl) 1997-01-31
IL116109A (en) 1998-12-27
DE69208144T2 (de) 1996-09-05
JP3229013B2 (ja) 2001-11-12
BG98310A (bg) 1994-01-03
IL101932A (en) 1997-04-15
US5663320A (en) 1997-09-02
JPH05186463A (ja) 1993-07-27
CA2069063A1 (en) 1992-11-22
SK129393A3 (en) 1994-07-06
FI20001900A (fi) 2000-08-29
US5744596A (en) 1998-04-28
FI935151A0 (fi) 1993-11-19
US5693787A (en) 1997-12-02
RU2223960C2 (ru) 2004-02-20
CN1050603C (zh) 2000-03-22
CN1067654A (zh) 1993-01-06
TW467907B (en) 2001-12-11
PL168910B1 (pl) 1996-05-31
NZ242818A (en) 1994-04-27
KR920021575A (ko) 1992-12-18
MX9202404A (es) 1993-08-31
GR3024617T3 (en) 1997-12-31
NO300593B1 (no) 1997-06-23
KR100242921B1 (ko) 2000-03-15
IE76741B1 (en) 1997-11-05
MX9202395A (es) 1993-02-01
IE921618A1 (en) 1992-12-02
NO301010B1 (no) 1997-09-01
HU223838B1 (hu) 2005-02-28
FI935150A (fi) 1993-11-19
US5696254A (en) 1997-12-09
NO921989D0 (no) 1992-05-20
CN1035555C (zh) 1997-08-06
GT199800047A (es) 1999-08-26
CN1229078A (zh) 1999-09-22

Similar Documents

Publication Publication Date Title
FI935150A (fi) Foerfaranden foer diastereoselektiv syntes av nukleosider
RU93058362A (ru) Способы диастереоселективного синтеза нуклеозидов, промежуточные соединения, способы получения промежуточных соединений
RU93058554A (ru) Способы диастереоселективного синтеза нуклеозидов

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: SHIRE BIOCHEM INC.

Free format text: SHIRE BIOCHEM INC.

PC Transfer of assignment of patent

Owner name: SHIRE CANADA INC.

Free format text: SHIRE CANADA INC.

MA Patent expired